User contributions for Kosar Doraghi

18:1718:17, 20 August 2024 diff hist +60‎ Template:KDRG ‎ →‎Pages Authored/Co-authored/Collaborated current
18:1018:10, 20 August 2024 diff hist +1,022‎ N COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation) ‎ Created page with "===Vaccination for Stable COPD=== *Influenza vaccination is recommended for people with COPD (Evidence B). *The WHO and CDC recommend SARS-CoV-2 (COVID-19) vaccination for people with COPD (Evidence B). *The CDC recommends one dose of 20-valent pneumococcal conjugate vaccine (PCV20) or one dose of 15-valent pneumococcal conjugate vaccine (PCV15) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for people with COPD (Evidence B). *Pneumococcal vaccinatio..." current

03:1603:16, 7 August 2024 diff hist +9‎ Template:KDRG ‎No edit summary
03:1303:13, 7 August 2024 diff hist +39‎ Nirogacestat ‎No edit summary current
03:1203:12, 7 August 2024 diff hist +39‎ Lasmiditan ‎No edit summary current
03:1203:12, 7 August 2024 diff hist +39‎ Ponesimod ‎No edit summary current
03:1103:11, 7 August 2024 diff hist +39‎ Dasiglucagon ‎No edit summary current
03:1103:11, 7 August 2024 diff hist +39‎ Vericiguat ‎No edit summary current
03:1003:10, 7 August 2024 diff hist +39‎ Spevigo- spesolimab-sbz ‎No edit summary current
03:0903:09, 7 August 2024 diff hist +40‎ Tapinarof ‎No edit summary current

20:5020:50, 23 June 2024 diff hist +694‎ Rytelo ‎No edit summary current
20:4320:43, 23 June 2024 diff hist 0‎ N File:IMG 1243.jpeg ‎No edit summary current
20:4320:43, 23 June 2024 diff hist 0‎ N File:IMG 1247.jpeg ‎No edit summary current
20:4320:43, 23 June 2024 diff hist 0‎ N File:IMG 1244.jpeg ‎No edit summary current

02:4602:46, 21 June 2024 diff hist +12‎ Template:KDRG ‎No edit summary
02:4602:46, 21 June 2024 diff hist +10,735‎ N Rytelo ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:K.doraghi@yahoo.com] |genericName=Imetelstat |aOrAn=an |drugClass=oligonucleotide telomerase inhibitor |indicationType=treatment |indication=oligonucleotide telomerase inhibitor adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are..."
02:3402:34, 21 June 2024 diff hist 0‎ N File:IMG 1242.jpeg ‎No edit summary current
02:3302:33, 21 June 2024 diff hist 0‎ N File:IMG 1246.jpeg ‎No edit summary current

02:3302:33, 13 June 2024 diff hist +73‎ Template:KDRG ‎No edit summary
02:3102:31, 13 June 2024 diff hist +30‎ Xolremdi ‎No edit summary current
02:2902:29, 13 June 2024 diff hist 0‎ N File:IMG 1241.jpeg ‎No edit summary current
02:2502:25, 13 June 2024 diff hist +14‎ Template:KDRG ‎No edit summary

23:0223:02, 8 June 2024 diff hist +15,628‎ N Xolremdi ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=mavorixafor |aOrAn=a |drugClass=CXC chemokine receptor 4 (CXCR4) antagonist |indicationType=treatment |indication=patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. |hasBlackBoxWarning=Yes |adverseReactions=thrombocytopenia, pityr..."
22:5222:52, 8 June 2024 diff hist 0‎ N File:IMG 1240.jpeg ‎No edit summary current
22:5022:50, 8 June 2024 diff hist 0‎ N File:IMG 1239.jpeg ‎No edit summary current
22:4922:49, 8 June 2024 diff hist 0‎ N File:IMG 1238.jpeg ‎No edit summary current

03:2803:28, 2 June 2024 diff hist +581‎ WINREVAIR ‎No edit summary current
02:5402:54, 2 June 2024 diff hist 0‎ N File:IMG 1235.jpeg ‎No edit summary current
02:5302:53, 2 June 2024 diff hist 0‎ N File:IMG 1234.jpeg ‎No edit summary current
02:5202:52, 2 June 2024 diff hist 0‎ N File:IMG 1231.jpeg ‎No edit summary current
02:5102:51, 2 June 2024 diff hist 0‎ N File:IMG 1232.jpeg ‎No edit summary current
02:4902:49, 2 June 2024 diff hist 0‎ N File:IMG 1230.jpeg ‎No edit summary current
02:4902:49, 2 June 2024 diff hist 0‎ N File:IMG 1227.jpeg ‎No edit summary current
02:4802:48, 2 June 2024 diff hist 0‎ N File:IMG 1236.jpeg ‎No edit summary current
02:4602:46, 2 June 2024 diff hist 0‎ N File:IMG 1237.jpeg ‎No edit summary current
02:4102:41, 2 June 2024 diff hist 0‎ N File:IMG 1226.jpeg ‎No edit summary current

03:2103:21, 1 June 2024 diff hist +15‎ Template:KDRG ‎No edit summary
03:2003:20, 1 June 2024 diff hist +16,566‎ N WINREVAIR ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sotatercept-csrk |aOrAn=an |drugClass=activin signaling inhibitor |indicationType=treatment |indication=adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events |hasBlackBoxWarning=Yes |adverseReactions=headache, epistaxis, rash, telangiect..."

02:0102:01, 23 May 2024 diff hist +18‎ Template:KDRG ‎No edit summary
02:0002:00, 23 May 2024 diff hist +16,419‎ N Aprocitentan ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar.Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=aprocitentan |aOrAn=an |drugClass=endothelin receptor antagonist |indicationType=treatment |indication=hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs |hasBlackBoxWarning=Yes |adverseReactions=edema/fluid retention and anemia |blackBoxWarningTitle=W..." current
02:0002:00, 23 May 2024 diff hist −3‎ Template:KDRG ‎No edit summary
01:4901:49, 23 May 2024 diff hist 0‎ N File:IMG 1225.jpeg ‎No edit summary current
01:2801:28, 23 May 2024 diff hist 0‎ N File:IMG 1224.jpeg ‎No edit summary current
01:2801:28, 23 May 2024 diff hist 0‎ N File:IMG 1223.jpeg ‎No edit summary current

Navigation menu